START-UP’s monthly update on technology transfer deals—licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.
Arch Biopartners gets option to University of Alberta's IBS diagnostic technology
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
After dropping its lead program in December, Spruce has been exploring strategic options – and thinks it has a de-risked path for MPS IIIB therapy tralesinidase from BioMarin.
Private Company Edition: After Q1 venture capital investment slumped relative to 2024 totals due to declines in both smaller financings and mega-rounds, Q2 started off with six $100m-plus financings in the first half of April after there were only three in February and six in all off March.
